The federal Project Grant award R44NS125892 for $766,451.00, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), supports the development of tissue engineered neuromuscular interfaces (TE-NMIs) from GalSafe neurons by Axonova Medical LLC. The funding enables Axonova to establish CGMP-like manufacturing processes, define critical quality attributes and release criteria, and determine an effective dosing paradigm for the TE-NMIs. Additionally, the grant supports in vivo porcine studies to assess the efficacy of TE-NMIs in promoting functional recovery following delayed nerve repair. This Project Grant, awarded in April 2024, builds upon Axonova's previous NINDS-funded work in developing TE-NMIs as a novel solution for treating major peripheral nerve injuries.
Generated 3/4/25, 6:17 AM